rhinitis etc. These cells' activity is tightly regulated by intracellular calcium signalling. Therefore, understanding how Th2 lymphocytes and mast cell are regulated by calcium ion channels may provide new approaches in treating allergic airway diseases. In particular, the ORAI1 channel mediated intracellular Ca 2+ increase is an important driver for the release and synthesis of allergic inflammatory mediators such as histamine, leukotrienes, and cytokines (IL-4, IL-13 etc.). Spirodela polyrhiza (SP) extract has been reported to have antiinflammatory and anti-allergic effects, such as the inhibition of proinflammatory cytokine secretion and mast cell degranulation. In this study, we examined the effects of the SP extract and its chemical constituents on the modulation of ORAI1 channels to evaluate their potential use as therapeutic agents for the treatment of allergic diseases.
enes, and cytokines .
Spirodela polyrhiza (SP) extract has been reported to have antiinflammatory and anti-allergic effects, such as the inhibition of proinflammatory cytokine secretion and mast cell degranulation. In this study, we examined the effects of the SP extract and its chemical constituents on the modulation of ORAI1 channels to evaluate their potential use as therapeutic agents for the treatment of allergic diseases.
Methods: A 30% ethanol extraction of SP (SP EtOH ) was prepared. T lymphocytes and mast cells were treated with the SP extract or its five chemical constituents including vitexin. Modulation of ORAI1 activity was measured using a conventional whole-cell patch-clamp technique.
T cell proliferation assay and β-hexosaminidase assay were performed.
Results: In Jurkat T lymphocytes, we found that 3 mg/mL SP EtOH inhibited I CRAC by 81.0 AE 11.1%, while one of its constituents (vitexin; 100 μM) inhibited I CRAC by 48.9 AE 8.71%. Investigation of human primary T cell proliferation induced by co-stimulation with antibodies to cluster of differentiation 3 and 28 and of RBL-2H3 mast cell degranulation following IgE-antigen complex stimulation revealed that 100 μM vitexin inhibited both T cell proliferation (by 34.8 AE 6.08%) and mast cell degranulation (by 36.7 AE 0.07%); these effects were concentration dependent and no cytotoxicity was observed.
Conclusion: Vitexin represents a candidate for the development of therapeutic agents to prevent and treat allergic airway diseases. Background and Aims: The expression of Na-K-2Cl cotransporter 1 (NKCC1) in the alveolar epithelium is responsible for fluid homeostasis in acute lung injury (ALI). Increasing evidence suggests that NKCC1 is associated with inflammation in ALI. We hypothesized that inhibiting NKCC1 would attenuate injury of alveolar epithelium after ischemiareperfusion (IR) by modulating nuclear factor-κB (NF-κB) and p38 mitogen-activated protein kinase (p38 MAPK) pathways.
Methods: IR-ALI was induced by producing 30 min of ischemia followed by 90 min of reperfusion in situ in an isolated and perfused rat lung model. The rats were randomly allotted into four groups comprising two control groups and two IR groups with and without bumetanide. Human alveolar A549 cells were cultured in control and hypoxia-reoxygenation (HR) conditions with or without bumetanide.
Results: In IR-ALI, bumetanide attenuates the activation of epithelial phosphorylated-NKCC1, and significantly attenuated the increases in lung weight gain, vascular filtration coefficient (Kf ), the ratio of wet weight to dry weight ratio (W/D) and the ratio of lung weight to body weight (LW/BW) in the IR group. Compared with the control group, NF-κB p65 and p38 MAPK were increased after IR and HR, which were reduced by bumetanide. The expressions of Bcl-2 and caspase 3 were significantly lower in HR group than in the control group, which were increased by bumetanide treatment. Background and Aims: Cigarette smoking is known to affect gut microbiota. However, there have been few large scale studies on the relationship between smoking and gut microbiota in relatively healthy people. this study investigated the relationship between smoking status and the composition of human gut microbiota.
Conclusion
Methods: A total of 758 men were selected from a Korean health screening cohort and divided into three groups: never smokers (n = 288), former smokers (n = 267), and current smokers (n = 203). Variable V3 and V4 regions of the 16S rRNA were amplified, and de novo operational taxonomic unit clustering were performed using the UPARSE pipeline. Microbial composition analyses were conducted using QIIME2.
Results: Among the three groups, there was no difference in alpha diversity. However, Jaccard-based beta diversity among the three groups showed significant difference (P = 0.015). Pairwise PERMANOVA tests between never and former smokers did not show a difference; however, there was significant difference between never and current smokers (P = 0.017) and between former and current smokers (P = 0.011). Weighted UniFrac-based beta diversity also showed significant difference among the three groups (P = 0.038), and pairwise PERMANOVA analysis of never and current smokers showed significant difference (P = 0.01). In analysis of bacterial composition, current smokers had an increased proportion of phylum Bacteroidetes with decreased Firmicutes and Proteobacteria compared with never smokers, whereas there were no differences between former and never smokers.
Conclusion:
Gut microbiota composition of current smokers was significantly different from that of never smokers, though there was no difference in terms of alpha diversity. Additionally, there was no difference in gut microbiota composition between never and former smokers. 
